Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Recent Quotes

View More
Symbol Price Change (%)
AMZN  205.42
+4.27 (2.12%)
AAPL  264.79
+0.91 (0.34%)
AMD  200.07
-3.01 (-1.48%)
BAC  53.34
+0.60 (1.14%)
GOOG  303.57
+0.75 (0.25%)
META  638.28
-1.01 (-0.16%)
MSFT  400.06
+3.19 (0.81%)
NVDA  189.81
+4.84 (2.62%)
ORCL  156.00
+2.03 (1.32%)
TSLA  414.87
+4.24 (1.03%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.